Kris Sachsenmeier

Title: Innovations of Kris Sachsenmeier

Introduction

Kris Sachsenmeier is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic agents targeting CD73. With a total of 5 patents to his name, Sachsenmeier's work has the potential to impact cancer treatment significantly.

Latest Patents

One of his latest patents is titled "Binding molecules specific for CD73 and uses thereof." This patent provides anti-CD73 binding molecules, including antibodies and their antigen-binding fragments. The disclosure also includes pharmaceutical formulations that utilize these compositions, along with methods for diagnosing and treating diseases associated with CD73 expression, such as cancer. The therapeutic approaches outlined in this patent include direct therapy with anti-CD73 binding molecules, adjuvant therapy with other anticancer agents, and combination therapies with chemotherapy. Another significant patent is "Therapeutic combinations comprising anti-CD73 antibodies and uses thereof," which features anti-CD73 antibodies and A2A receptor inhibitors aimed at reducing tumor-mediated immunosuppression.

Career Highlights

Kris Sachsenmeier is currently employed at MedImmune Limited, where he continues to innovate in the field of therapeutic development. His work focuses on creating effective treatments for cancer, leveraging his expertise in antibody technology.

Collaborations

Sachsenmeier collaborates with talented individuals such as Carl Hay and Erin Sult, who contribute to the advancement of their shared goals in biotechnology.

Conclusion

Kris Sachsenmeier's contributions to the field of biotechnology, particularly through his patents related to CD73, highlight his role as an influential inventor. His work at MedImmune Limited and collaborations with colleagues further enhance the potential for innovative cancer therapies.